Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study - Concepedia

Concepedia

Publication | Open Access

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study

DOI Full Paper Access

38

Citations

20

References

2020

Year

Tony Mok, Solange Peters, D. Ross Camidge, Johannes Noé, Shirish M. Gadgeel, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Krzysztof Konopa, Emanuela Pozzi, Ting Liu,

Journal of Thoracic Oncology

References

	Year	Citations

Page 1